ADDvise receives order worth USD 1.4 million

REG

Axelerist, an ADDvise Group company, has received an order from Vertex Pharmaceuticals, a global biotechnology company, for the sale and rental of medical and laboratory equipment. The order value amounts to USD 1.4 million. Delivery will take place over a four-year period starting in Q3 2024.

 

For further information, please contact:

Rikard Akhtarzand, CEO

+46 (0) 76-525 90 71

rikard.akhtarzand@addvisegroup.se

 

Important information

This information is such that ADDvise Group AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons above, on May 21, 2024, at 12:30 CEST.

 

About ADDvise

ADDvise is an international life science group. Operating a decentralised ownership model, we develop and acquire high quality companies within the business areas Lab and Healthcare. The Group comprises more than 20 companies and generates annual revenues of close to SEK 2 billion. ADDvise is listed on Nasdaq First North Premier Growth Market. Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com.

Datum 2024-05-21, kl 12:30
Källa Cision
Alla Aktier tipsar: Har du redan ett konto på Avanza? Varför inte skapa ett på Nordnet också och jämföra funktioner, courtage mm. Det tar inte lång tid, du fixar det direkt här med BankID
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet